Xenetic生物科学报告称,Q2收入达到预期水平,EPS收入为0.83美元和0.73M美元。 Xenetic Biosciences reports Q2 earnings meeting expectations, with EPS of ($0.83) and $0.73M revenue.

克塞尼特生物科学 (NASDAQ:XBIO) 报告了第二季度的收益,符合分析师的预期,每股收益为0.83美元,收入为0.73亿美元 (相对于0.54亿美元). Xenetic Biosciences (NASDAQ: XBIO) reported Q2 earnings, meeting analyst expectations with an EPS of ($0.83) and revenue of $0.73M (vs. $0.54M est.). 股票价格下跌0.14美元至3.15美元,市值为485万美元,收益率为-1.08美元,贝塔为2.29美元. Shares traded down $0.14 to $3.15, with a market cap of $4.85M, P/E of -1.08, and beta of 2.29. 生物制药公司侧重于推进个人化的CAR T平台技术,即用于B细胞淋巴瘤治疗的XCART。 The biopharmaceutical firm focuses on advancing personalized CAR T platform technology, XCART, for B-cell lymphoma treatment.